Nexalin™ technology is a patented improvement and a continuing development of Dr. Katsnelson’s life’s work. Persistent innovation of this technology is one of Kalaco Scientific’s primary goals. Advancements will include various therapies for different indications, as well as technological advances. These indications for use are being researched and have not yet received FDA marketing authorization. Kalaco has new apparatus and method currently patent pending, and will continue to seek patents in this rapidly advancing therapeutic field.

Other areas of our clinical research include the following indications: Long-term relief of pain associated with Osteoarthritis; Parkinson’s, Post Surgical Pain, Depression, Anxiety and Insomnia.

Future areas of clinical research will include: Neuropathic pain (particularly Phantom pain)

	The research thus far has led to the following regulatory goals, clearances or approvals: In the United States, clearance for depression, anxiety and insomnia is already attained. Continued research is being planned to provide the clinical support for an additional clearance from the FDA for the “long-term relief of pain associated with osteoarthritis.”
	In the European Union, Kalaco has received the approval and CE Marking for the long term relief of musculoskeletal pain and the treatment of depression, anxiety and insomnia.
	In Switzerland, Kalaco has received the approval and acceptance of the CE Marking for relief of musculoskeletal pain and the treatment of depression, anxiety and insomnia.
	In Russia, Kalaco has approval of the Nexalin devices for use in medical practice.
	In Australia, Kalaco has received approval from the Therapeutic Goods Administration (TGA) - The equivalent of the United States FDA - for the relief of musculoskeletal pain, as well as the treatment of anxiety, depression, and insomnia.